Analysts Issue Forecasts for Mineralys Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:MLYS)

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Stock analysts at Lifesci Capital issued their FY2024 earnings estimates for Mineralys Therapeutics in a research note issued to investors on Tuesday, March 26th. Lifesci Capital analyst R. Katkhuda expects that the company will earn ($2.04) per share for the year. Lifesci Capital currently has a “Outperform” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.64) per share.

Mineralys Therapeutics Trading Down 0.5 %

Shares of Mineralys Therapeutics stock opened at $12.78 on Thursday. The business has a fifty day simple moving average of $13.17 and a two-hundred day simple moving average of $10.10. The firm has a market capitalization of $634.27 million and a P/E ratio of -6.39. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $17.70.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.24.

Insider Buying and Selling

In related news, major shareholder Samsara Biocapital Gp, Llc acquired 555,555 shares of the stock in a transaction dated Monday, February 12th. The shares were purchased at an average cost of $13.50 per share, with a total value of $7,499,992.50. Following the transaction, the insider now directly owns 5,074,916 shares in the company, valued at $68,511,366. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently bought and sold shares of MLYS. CWM LLC purchased a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth $25,000. PNC Financial Services Group Inc. lifted its position in shares of Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock valued at $35,000 after acquiring an additional 4,099 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Mineralys Therapeutics in the fourth quarter valued at approximately $41,000. New York State Common Retirement Fund purchased a new position in shares of Mineralys Therapeutics in the first quarter valued at approximately $53,000. Finally, California State Teachers Retirement System purchased a new position in Mineralys Therapeutics during the first quarter worth approximately $70,000. Institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.